在与肝脏功能障碍相关的瘤中Torsemide
Rajesh Upadhyay1, Mangesh Tiwaskar2, Ramesh Dargad3
1Senior Director and Head, Department of Gastroenterology, Hepatology and Endoscopy, Max Superspeciality Hospital, Delhi, India, Corresponding Author.
The Journal of the Association of Physicians of India
|September 18, 2024
概括
不补偿性肝硬化时的肝会导致液体积累. 西米德 (Torsemide) 是一种利尿剂,是西米德 (furosemide) 的更安全,更有效的替代品,用于治疗肝硬化患者的.
科学领域:
- 肝病学和病学 肝病学和病学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 脱补偿性肝硬化时的肝和是由于蛋白质合成减少,鼻状水静压增加和白蛋白水平降低而产生的.
- 目前的治疗指南建议阿尔多激素抗剂作为肝硬化相关的第一线治疗.
- 对于严重或复发性炎,通常需要用阿尔多激素抗剂和循环利尿剂进行联合治疗.
研究的目的:
- 为了比较torsemide与furosemide在患有肝硬化相关的患者中的疗效和安全性.
- 评估torsemide对furosemide在肝脏疾病中的利尿疗法的药理学优势.
主要方法:
- 对比torsemide和furosemide在肝硬化和炎患者中的临床研究的综述.
- 对药理性质的分析,包括尿和利尿作用,生物可用性,半衰期和副作用概况.
主要成果:
- 与相应剂量的罗塞米德相比,Torsemide表现出更强的尿和利尿作用.
- 托塞米德的低血发病率较低,作用时间较长,生物可用性更高,半衰期延长.
- 临床数据表明,torsemide与较少的并发症有关,并且是一种更安全,更可接受的治疗选择.
结论:
- 托尔塞米德 (Torsemide) 是比罗塞米德 (furosemide) 更有效,更安全的治疗选择,用于治疗肝硬化不补偿的患者的.
- 托塞米德的独特药理特征支持其在这种患者群体中优先使用.
相关概念视频
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
558
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
558
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
473
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
473
01:29Disorder of Water Balance
314
Water balance disorders are medical conditions that occur when there is a deviation from the body's water volume or osmolarity, disrupting normal homeostasis and leading todehydration, hypotonic hydration, hyperhydration, edema, or water intoxication.
Dehydration
Dehydration occurs when the body loses fluids (particularly water).
Causes:
The major causes of dehydration include excessive sweating, fever, vomiting, diarrhea, and diuresis.
Signs and Symptoms:
Symptoms primarily include intense...
Dehydration
Dehydration occurs when the body loses fluids (particularly water).
Causes:
The major causes of dehydration include excessive sweating, fever, vomiting, diarrhea, and diuresis.
Signs and Symptoms:
Symptoms primarily include intense...
314
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
139
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
139
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396